TAT and cancer: It would be interesting to test these Tat mutants and LRAs in the context of full-length virus in a primary cell model of latency or ex vivo given the different landscape of cellular factors in rCD4+ T cells compared to a cancer cell line that affect the capacity of a cell to reactivate a latent provirus.